Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein–Ligand X-ray Studies
Citations Over TimeTop 12% of 2013 papers
Abstract
The design, synthesis, and biological evaluation of a series of HIV-1 protease inhibitors incorporating stereochemically defined fused tricyclic P2 ligands are described. Various substituent effects were investigated to maximize the ligand-binding site interactions in the protease active site. Inhibitors 16a and 16f showed excellent enzyme inhibitory and antiviral activity, although the incorporation of sulfone functionality resulted in a decrease in potency. Both inhibitors 16a and 16f maintained activity against a panel of multidrug resistant HIV-1 variants. A high-resolution X-ray crystal structure of 16a-bound HIV-1 protease revealed important molecular insights into the ligand-binding site interactions, which may account for the inhibitor's potent antiviral activity and excellent resistance profiles.
Related Papers
- → Nine Crystal Structures Determine the Substrate Envelope of the MDR HIV-1 Protease(2011)24 cited
- → Models of HIV-1 protease with peptides representing its natural substrates(1998)7 cited
- → Deep recurrent neural networks in HIV-1 protease cleavage classification(2017)3 cited
- → Coarse-Grained Modeling of the HIV–1 Protease Binding Mechanisms: I. Targeting Structural Flexibility of the Protease Flaps and Implications for Drug Design(2009)
- → Determination of the Substrate Envelope for Multidrug‐Resistant HIV‐1 Protease(2008)